First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection
August 28, 2026
August 28, 2026
CLEVELAND, Ohio, Aug. 28 [Category: BizHospital] -- The Cleveland Clinic posted the following news release:
* * *
First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection
*
Findings from a Phase 1 clinical trial led by Cleveland Clinic show a single injection of Kylo-11 produced reductions in lipoprotein(a) levels, with the highest doses reducing levels by approximately 95-97% and maint . . .
* * *
First in Human Long-Acting Gene Silencing Therapy Significantly Lowers Heart Disease Risk Marker with One Injection
*
Findings from a Phase 1 clinical trial led by Cleveland Clinic show a single injection of Kylo-11 produced reductions in lipoprotein(a) levels, with the highest doses reducing levels by approximately 95-97% and maint . . .